SCHEMBL4929256

SCHEMBL4929256

CCCN1CCc2cc(C(=O)O)ccc21

nearest known ligand 0.57

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 4/20 0.57
MEN1 O00255 3/20 0.57
KMT2A Q03164 3/20 0.57
KDM4E B2RXH2 2/20 0.57
MAPT P10636 2/20 0.57
L3MBTL1 Q9Y468 2/20 0.57
LMNA P02545 1/20 0.57
TP53 P04637 1/20 0.57
GAA P10253 1/20 0.57
CASP1 P29466 1/20 0.57
HTT P42858 1/20 0.57
CASP7 P55210 1/20 0.57
SMAD3 P84022 1/20 0.57
HSD17B10 Q99714 1/20 0.57
ACHE P22303 4/20 0.55
KDM4C Q9H3R0 3/20 0.47
KDM4A O75164 2/20 0.47
KDM2B Q8NHM5 1/20 0.47
POLB P06746 1/20 0.46
TDP1 Q9NUW8 1/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4934508 0.90 ACHE (0.58) ALDH1A1MEN1KMT2AKDM4EMAPT
SCHEMBL20178650 0.88 ACHE (0.54) ALDH1A1MEN1KMT2AKDM4EMAPT
SCHEMBL30197112 0.87 ALDH1A1 (0.53) ALDH1A1MEN1KMT2AKDM4EMAPT
SCHEMBL845803 0.83 ALDH1A1 (0.56) ALDH1A1MEN1KMT2AKDM4EMAPT
SCHEMBL2759079 0.83 MAPT (0.62) ALDH1A1MEN1KMT2AKDM4EMAPT
SCHEMBL20178649 0.81 ALDH1A1 (0.52) ALDH1A1MEN1KMT2AKDM4EMAPT
SCHEMBL3349545 0.80 ACHE (0.47) ALDH1A1MEN1KMT2AKDM4EMAPT
SCHEMBL2759073 0.80 TP53 (0.58) ALDH1A1MEN1KMT2AKDM4EMAPT
SCHEMBL2819895 0.80 ACHE (0.51) ALDH1A1MEN1KMT2AKDM4EMAPT
SCHEMBL13170391 0.79 ACHE (0.48) ALDH1A1MEN1KMT2AKDM4EMAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8394828-B2 Quinoline-derived amide modulators of vanilloid VR1 receptor JANSSEN PHARMACEUTICA, NV (BE) 2013-03-12 US disclosed
US-20080300236-A1 QUINOLINE-DERIVED AMIDE MODULATORS OF VANILLOID VR1 RECEPTOR CODD ELLEN 2008-12-04 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080300236-A1 QUINOLINE-DERIVED AMIDE MODULATORS OF VANILLOID VR1 RECEPTOR TRPV1, OPRL1, TRPV2 ALDH1A1 1216/4885MEN1 4610/4885KMT2A 2415/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.